Biogen licenses a possible immune drug from OrbiMed-backed biotech
Biogen Licenses Immune Drug from Vanqua Bio Biogen has licensed a preclinical drug from Vanqua Bio, designed to inhibit "C5aR1", a part of the immune system that regulates inflammation.